Rifaximin SSD

DRUG3 trials

Sponsors

Philip Kern, Bausch Health Americas, Inc.

Conditions

Hepatic EncephalopathyInsulin ResistanceMetabolic SyndromeObese

Phase 2

Blood Lipopolysaccharide (LPS) Rifaximin Study

CompletedNCT02124512

Philip KernInsulin Resistance, Metabolic Syndrome, Obese

Start: 2015-03-31End: 2019-05-31Updated: 2019-08-21

Phase 3

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Active, not recruitingNCT05071716

Bausch Health Americas, Inc.Hepatic Encephalopathy

Start: 2022-04-07End: 2025-09-30Updated: 2025-07-24

Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

Active, not recruitingNCT05297448

Bausch Health Americas, Inc.Hepatic Encephalopathy

Start: 2022-08-03End: 2026-01-31Target: 466Updated: 2025-09-10